PF 3491165
Alternative Names: PF-3491165Latest Information Update: 13 Aug 2007
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antihyperlipidaemics; Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 20 Dec 2006 Phase-I clinical trials in Atherosclerosis in USA (unspecified route)